King's College London

Research portal

The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset

Research output: Contribution to journalArticlepeer-review

Peter M.A. Calverley, Alberto Papi, Clive Page, Paola Rogliani, Roberto W. Dal Negro, Mario Cazzola, Arrigo F. Cicero, Jadwiga A. Wedzicha

Original languageEnglish
Pages (from-to)1909-1920
Number of pages12
JournalInternational Journal of COPD
Volume17
DOIs
Published2022

Bibliographical note

Funding Information: Medical writing assistance was provided by Deirdre Elmhirst, PhD, of Elmhirst Scientific Consultancy Limited, funded by Edmond Pharma. Funding Information: P Calverley reports personal fees from Recipharm, during the conduct of the study; personal fees from Edmond Pharma, Novartis, Phillips Respironics, and Genentech, outside the submitted work. P Rogliani participated as a lecturer and advisor in scientific meetings sponsored by Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline (GSK), Menarini Group, MSD, Mundipharma, Novartis, Edmond Pharma and Roche. Her department was funded by Almirall, Boehringer Ingelheim, Chiesi Farmaceutici, Novartis, and Zambon. J Wedzicha reports grants from AstraZeneca, personal fees from Chiesi Farmaceutici, Novartis, grants, personal fees from GSK, grants from Boehringer Ingelheim, personal fees from Gilead, grants from Genentech, outside the submitted work. A Papi reports grants from Chiesi Farmaceutici, AstraZeneca, GSK, Boehringer Ingelheim, Teva, Sanofi, personal fees from Chiesi Farmaceutici, AstraZeneca, GSK, Novartis, Sanofi, IQVIA, Avillion, Elpen Pharmaceuticals, MSD, Boehringer Ingelheim, Menarini, Zambon, Mundipharma, Teva, Edmond Pharma, outside the submitted work. M Cazzola and C Page are consultants to Edmond Pharma who manufactures and markets erdosteine. C Page reports personal fees from Edmond Pharma, during the conduct of the study; equity from Verona Pharma, personal fees from Glycos Innovation, personal fees from Eurodrug, personal fees from worldwide clinical trial, outside the submitted work; and Non Executive Director of Epiendo Pharmaceuticals. AF Cicero reported personal fees from Edmond Pharma. The authors report no other conflicts of interest in this work. Publisher Copyright: © 2022 Calverley et al. This work is published and licensed by Dove Medical Press Limited.

King's Authors

Abstract

Purpose: To explore the effect of erdosteine on COPD exacerbations, health-related quality of life (HRQoL), and subjectively assessed COPD severity. Patients and methods: This post-hoc analysis of the RESTORE study included participants with COPD and spirometrically moderate (GOLD 2; post-bronchodilator forced expiratory volume in 1 second [FEV1] 50‒79% predicted; n = 254), or severe airflow limitation (GOLD 3; post-bronchodilator FEV1 30‒49% predicted; n = 191) who received erdosteine 300 mg twice daily or placebo added to usual maintenance therapy for 12 months. Antibiotic and oral corticosteroid use was determined together with patient-reported HRQoL (St George’s Respiratory Questionnaire, SGRQ). Patient and physician subjective COPD severity scores (scale 0‒4) were rated at baseline, 6 and 12 months. Data were analyzed using descriptive statistics for exacerbation severity, COPD severity, and treatment group. Comparisons between treatment groups used Student’s t-tests or ANCOVA as appropriate. Results: Among GOLD 2 patients, 43 of 126 erdosteine-treated patients exacerbated (7 moderate-to-severe exacerbations), compared to 62 of 128 placebo-treated patients (14 moderate-to-severe exacerbations). Among those with moderate-to-severe exacerbations, erdosteine-treated patients had a shorter mean duration of corticosteroid treatment (11.4 days vs 13.3 days for placebo, P = 0.043), and fewer patients required antibiotic treatment with/without oral corticosteroids (71.4% vs 85.8% for placebo, P < 0.001). Erdosteine-treated GOLD 2 patients who exacerbated showed significant improvements from baseline in SGRQ total scores and subjective disease severity scores (patient-and physician-rated), compared with placebo-treated patients regardless of exacerbation severity. Among GOLD 3 patients, there were no significant differences between treatment groups on any of these measures. Conclusion: Adding erdosteine to the usual maintenance therapy of COPD patients with moderate airflow limitation reduced the number of exacerbations, the duration of treatment with corticosteroids and the episodes requiring treatment with antibiotics. Additionally, treatment with erdosteine improved HRQoL and patient-reported disease severity.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454